KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Short term Debt (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Short term Debt for 11 consecutive years, with $710.7 million as the latest value for Q3 2025.

  • Quarterly Short term Debt changed N/A to $710.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $710.7 million through Sep 2025, changed N/A year-over-year, with the annual reading at $13.3 million for FY2022, 85.09% down from the prior year.
  • Short term Debt for Q3 2025 was $710.7 million at Halozyme Therapeutics, up from $13.3 million in the prior quarter.
  • The five-year high for Short term Debt was $710.7 million in Q3 2025, with the low at $13.3 million in Q3 2022.
  • Average Short term Debt over 3 years is $142.5 million, with a median of $89.3 million recorded in 2021.
  • The sharpest move saw Short term Debt surged 3014.45% in 2021, then crashed 85.09% in 2022.
  • Over 3 years, Short term Debt stood at $89.4 million in 2021, then plummeted by 85.09% to $13.3 million in 2022, then soared by 5229.87% to $710.7 million in 2025.
  • According to Business Quant data, Short term Debt over the past three periods came in at $710.7 million, $13.3 million, and $13.3 million for Q3 2025, Q4 2022, and Q3 2022 respectively.